A pivotal study comparing secukinumab (Cosentyx) with bimekizumab for the treatment of moderate to severe chronic plaque psoriasis was published on January 1, 2021. The publication, titled "Bimekizumab versus Secukinumab in Plaque Psoriasis," makes new comparative efficacy and safety data available for these biologic therapies.
Background
Secukinumab is an interleukin-17A (IL-17A) inhibitor approved for various inflammatory conditions, including moderate to severe chronic plaque psoriasis. Plaque psoriasis is a chronic autoimmune disease characterized by red, scaly patches on the skin, significantly impacting patients' quality of life. Biologic therapies like secukinumab represent important treatment options for patients who have not responded to or cannot tolerate other systemic treatments.
Trial design
The published research, known as the BE RADIANT study, was designed to evaluate the efficacy and safety of bimekizumab compared to an active comparator, secukinumab, in adult subjects suffering from moderate to severe chronic plaque psoriasis. This pivotal study aimed to provide head-to-head comparative data between two distinct biologic treatments for this dermatological condition.
What this means
The publication of the BE RADIANT study provides clinicians and researchers with important comparative data on secukinumab and bimekizumab for moderate to severe chronic plaque psoriasis. This head-to-head comparison is crucial for understanding the relative performance of these biologic therapies, informing treatment decisions, and guiding future research in the management of this chronic skin condition. The availability of this data allows for a direct assessment of their respective efficacy and safety profiles in a real-world clinical context.
Source
The information regarding this pivotal study was published in the New England Journal of Medicine, as cited by PubMed, on January 1, 2021. The article, titled "Bimekizumab versus Secukinumab in Plaque Psoriasis," is accessible via pubmed.ncbi.nlm.nih.gov.